BTIG Initiates Coverage On Ambrx Biopharma with Buy Rating, Announces Price Target of $26
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Kaveri Pohlman has initiated coverage on Ambrx Biopharma (NASDAQ:AMAM) with a Buy rating and a price target of $26.
September 12, 2023 | 9:57 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ambrx Biopharma has been initiated with a Buy rating by BTIG, with a price target of $26.
The initiation of coverage by BTIG with a Buy rating is a positive signal for Ambrx Biopharma. The price target of $26 suggests that the analyst sees significant upside potential in the stock. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100